Sanofi (SNYNF) Wednesday reported positive data from Phase 2 study of frexalimab in participants with relapsing multiple sclerosis (MS) at 48-weeks.
Results from the study showed that 96 percent of patients who received high-dose of frexalimab were free of Gd+ T1 lesions at week 48. Also, annualized relapse rate was low at 0.04 over the 48-week treatment period.
These data will be presented today at the American Academy of Neurology (AAN) 2024 Annual Meeting in Denver, Colorado.
Sanofi has initiated phase 3 studies of frexalimab in relapsing MS and non-relapsing secondary progressive MS.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.